Cellectis SA (NASDAQ:CLLS)
| 6.74 Delayed Data As of 4:00pm ET |  +0.04 / +0.60%Today’s Change | 6.70 Today|||52-Week Range 34.71 | -17.00% Year-to-Date |
Latest CLLS News | Press Releases
| Allogene (ALLO) Clinical Hold on CAR-T Studies Removed by FDA Jan 11 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 6.70 |
| Today’s open | 6.82 |
| Day’s range | 6.72 - 7.10 |
| Volume | 22,986 |
| Average volume (3 months) | 224,321 |
| Market cap | $331.4M |
Data as of 4:00pm ET, 01/20/2022
Growth & Valuation
| Earnings growth (last year) | +20.70% |
| Earnings growth (this year) | -62.17% |
| Earnings growth (next 5 years) | +1.50% |
| Revenue growth (last year) | +386.83% |
| P/E ratio | NM |
| Price/Sales | 15.55 |
| Price/Book | 1.13 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| GSGTFGensight Biologics S... | 0.00 | 0.00% |
| WWHCW World Corp | 0.00 | 0.00% |
| LQDALiquidia Corp | +0.02 | +0.35% |
| IMUXImmunic Inc | -0.80 | -7.07% |
Data as of 4:00pm ET, 01/20/2022
Financials
| Next reporting date | March 14, 2022 |
| EPS forecast (this quarter) | -$0.92 |
| Annual revenue (last year) | $73.9M |
| Annual profit (last year) | -$81.1M |
| Net profit margin | -109.64% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Paris, Ile-de-france |
Forecasts
